Novavax, Inc. (NVAX)

13.54 -0.07 (-0.53%) As of 09:48AM EDT. Market open.

Novavax, Inc.

700 Quince Orchard Road
Gaithersburg, MD 20878
United States
240 268 2000
https://www.novavax.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 1,543

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. John Charles Jacobs M.B.A.	President, CEO & Director	1.33M	N/A	1967
Mr. John Joseph Trizzino B.S., M.B.A.	President & COO	670.55k	N/A	1960
Mr. James Patrick Kelly C.F.A.	Executive VP, CFO & Treasurer	716.17k	N/A	1966
Mr. Mark Casey	Executive VP, Chief Legal Officer & Corporate Secretary	137.36k	N/A	1963
Mr. Richard P. Crowley	Executive VP & COO	N/A	N/A	1957
Dr. Robert Walker M.D.	Senior VP, Chief Medical Officer and Interim Head of R&D	N/A	N/A	N/A
Mr. Troy Morgan Esq., J.D.	Senior VP, Deputy General Counsel & Chief Compliance Officer	N/A	N/A	1971
Ms. Erika S. Trahan	Associate Director of Investor & Public Relations	N/A	N/A	N/A
Mr. Ian J. Watkins	Executive VP & Chief Human Resources Officer	N/A	N/A	1963
Ms. Silvia Taylor M.B.A.	Executive VP and Chief Corporate Affairs & Advocacy Officer	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Corporate Governance

Novavax, Inc.’s ISS Governance QualityScore as of September 1, 2024 is 6. The pillar scores are Audit: 8; Board: 5; Shareholder Rights: 5; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.